A randomized, open-label, parallel-group, single-dose comparative pharmacokinetics study of a candidate biosimilar WT-1 Trastuzumab with reference product in healthy male subjects

Chulabhorn Foundation by Chulabhorn Research Institute0 个研究点目标入组 70 人开始时间: 2024年7月4日最近更新: 2024年8月19日

适应症

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20 Years 至 50 Years（—）
性别: Male

入选标准

•In order to be eligible to participate in this study, an individual must meet all of the following criteria:
•1.Fully understands the purpose of the trial, and have a basic understanding of the pharmacological effects and possible adverse reactions of the drug under study;
•2.Is willing to sign a written informed consent document;
•3.Is a healthy male subject aged 20 to 50 years: Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, physical examination including blood pressure and pulse rate measurement, 12-lead electrocardiogram (ECG), and routine clinical laboratory tests;
•4.Has Body Mass Index (BMI) between 18.5 to 25.0 kg/m2 and a total body weight not less than 50 kg;
•5.Has left ventricular ejection fraction (LVEF) within the normal range as measured by echocardiogram within 4 weeks prior to randomization (LVEF not less than 60%);
•6.Agrees to use reliable contraceptive methods for both the subjects and their spouses/partners during the study period and for 6 months after the study drug infusion;
•7.Must not be currently participating in any other clinical study.

排除标准

•An individual who meets any of the following criteria will be excluded from participation in this study:
•1.Has evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic disease, or clinical findings at screening, based on interview, medical history and physical examination. However, untreated, asymptomatic seasonal allergies at the time of dosing is not excluded;
•2.Has Infection requiring systemic anti-infective treatment within 14 days of study randomization;
•3.Has clinically significant abnormalities in laboratory test results under investigator judgement;
•4.Has previous exposure to a monoclonal antibody or current use of other biologics;
•5.Has prior exposure to trastuzumab or related compounds;
•6.Has history of allergic or anaphylactic reaction to any of the excipients of this investigational product, Herceptin or any other drug;
•7.Has history of severe dyspnea at rest requiring supplementary oxygen therapy;
•8.Has history of surgery or major trauma within 12 weeks of screening, or surgery planned during the study;
•9.Has history of alcohol or drug abuse in the 12 months prior to screening; defined by more than 15 standard drinks per week. One standard drink contains 10 grams of alcohol; 330 mL of beer, 30 mL of spirit or 100 mL of wine.
•10.Whose spouses/partners plan to become pregnant;
•11.Use of prescription or non-prescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication (unless in the opinion of the Investigator, the medication did not interfere with the study procedures or compromise subject safety). Herbal supplements must be discontinued 14 days prior to the first dose of study medication;
•12.Has other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

研究者

发起方

Chulabhorn Foundation by Chulabhorn Research Institute

相似试验

进行中（未招募）

1 期

A randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (Levemir®) versus human insulin (NPH insulin), used in combination with insulin aspart as bolus insulin, in the treatment of pregnant women with type 1 diabetesTrial Phase: 3bType 1 diabetes

EUCTR2006-004861-33-DKovo Nordisk A/S460

进行中（未招募）

不适用

EUCTR2006-004861-33-IEovo Nordisk A/S407

进行中（未招募）

1 期

EUCTR2006-004861-33-GBovo Nordisk A/S460

进行中（未招募）

不适用

EUCTR2006-004861-33-ATovo Nordisk A/S460

进行中（未招募）

1 期

EUCTR2006-004861-33-FRovo Nordisk A/S